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Abstract Infection spreading in the skeletal system
leading to osteomyelitis can be prevented by the prolonged
administration of antibiotics in high doses. However sys-
temic antibiotherapy, besides its inconvenience and often
low efficacy, provokes numerous side effects. Thus, we
formulated a new injectable nanoparticle-loaded system for
the local delivery of vancomycin (Vanc) applied in a
minimally-invasive way. Vanc was encapsulated in poly(L-
lactide-co-glycolide) nanoparticles (NPs) by double-emul-
sification. The size (258 ± 11 nm), polydispersity index
(0.240 ± 0.003) and surface potential (-25.9 ± 0.2 mV)
of NPs were determined by dynamic light scattering and
capillary electrophoresis measurements. They have a
spherical morphology and a smooth topography as
observed using atomic force microscopy. Vanc loading and
encapsulation efficiencies were 8.8 ± 0.1 and
55.2 ± 0.5 %, respectively, based on fluorescence spec-
troscopy assays. In order to ensure injectability, NPs were
suspended in gellan gum and cross-linked with Ca2?; also a
portion of dissolved antibiotic was added to the system.
The resulting system was found to be injectable (extrusion
force 11.3 ± 1.1 N), reassembled its structure after
breaking as shown by rheology tests and ensured required
burst release followed by sustained Vanc delivery. The
system was cytocompatible with osteoblast-like MG-63
cells (no significant impact on cells’ viability was
detected). Growth of Staphylococcus spp. reference strains
and also those isolated from osteomyelitic joints was
inhibited in contact with the injectable system. As a result
we obtained a biocompatible system displaying ease of
application (low extrusion force), self-healing ability after
disruption, adjustable drug release and antimicrobial
properties.
1 Introduction
The traditional way of pathogenic bacteria elimination
from the musculoskeletal environment involves surgical
removal of necrotic tissue, osseous repair and antibiother-
apy applied for 3–6 weeks [1, 2]. If such treatment is not
effective, there is a risk that chronic disease called
osteomyelitis develops [1, 2]. Application of a glycopep-
tide antibiotic—vancomycin (Vanc) is advised for life-
threatening staphylococci infections that are a dominating
cause of osteomyelitis [3] and display resistance to typical
first-line antibiotics [4, 5]. However, the very poor
bioavailability of Vanc is an obstacle in the therapy,
because it is a large hydrophilic molecule that is moved
ineffectively across the lipophilic gastrointestinal mucosa
[6]. As a result, high doses of Vanc are used that in general
cause nephro- or ototoxicity, allergies and problems with
the gastrointestinal tract [6].
To deal with such problems local, site-specific routes of
Vanc delivery are being explored, e.g. based on calcium
phosphate cements or pastes [7], coatings on titanium
alloys [8], poly(methyl methacrylate) (PMMA) cements [9]
or polyurethane scaffolds [10]. However, there are some
drawbacks connected with this approach as well, because
of the invasive surgical implantation procedure and poorly
defined period of Vanc delivery [11].
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The system we suggest is based on a hydrogel
injectable matrix—gellan gum. Gellan gum (a polysac-
charide, produced by an aerobic fermentation of carbohy-
drates by Shingomonas elodea) forms a threefold double-
helical association. A ‘true gel structure’ of gellan gum is
formed by the aggregation of these associations and is
mediated by monovalent and/or divalent cations (e.g.
Ca2?) [12]. Gellan gum has already been processed into
mucoadhesive beads with ketoprofen [13], particles with
ciprofloxacin for dermal applications [14], or as a com-
posite with bioglass for bone tissue regeneration [15]. In
this study we postulate that thanks to the hydrogel-based
structure, the system will remain precisely at the site of
infection, without spreading to adjacent areas.
To provide the hydrogel with a therapeutic function, the
matrix was enriched with Vanc in two forms: dissolved and
encapsultaed in poly(lactide-co-glycolide) (PLGA)
nanoparticles. We postulated that such a combination
would ensure the proper drug release profile, i.e. a burst
release necessary to eliminate bacterial biofilm followed by
a prolonged sustained release, to prevent its reconstitution.
PLGA was selected as a material to fabricate Vanc-loaded
nanoparticles, because it is bioresorbable, approved by
Food and Drug Administration as well as European
Medicines Agency and its degradation rate can be finely
adjusted (i.e. by changing lactide to glycolide ratio,
molecular weight and chain structure) [16]. PLGA’s utility
for biomedical purposes has already been confirmed by its
broad medical application in the form of sutures, screws or
plates for osteosynthesis.
In general, our study aimed to fabricate an alternative
solution for osteomyelitis treatment using a low-invasive
procedure. We hypothesized that the material thanks to the
hydrogel structure would be easy to administer (injectable)
and thanks to addition of Vanc in two forms (dissolved and
encapsulated) would ensure site-specific and well tailored
drug delivery. The system composed was cross-linked to
provide the injection with proper compactness and elas-
ticity. We thoroughly assessed its handiness, accuracy of
dosing, drug release kinetics and mechanical properties.
Lastly we evaluated antimicrobial response towards the
bacterial strains gathered form osteomyelitic joints as well
as cytocompatibility in contact with osteoblast-like cells.
2 Materials and methods
2.1 Materials
Vancomycin hydrochloride, gellan gum (GelzanTM, low-
acyl form, MW 200-300 kDa) and polyvinyl alcohol (PVA,
Moviol 40-88), all of analytical grade, were obtained from
Sigma-Aldrich, Poland. Mercaptoethanol, methanol,
ethanol, isopropanol, orthophthaldialdehyde (OPA), phos-
phate-buffered saline concentrate (PBS buffer) and CaCl2
were all of analytical grade and were purchased from
POCh, Poland. All the experiments were conducted in ultra
high quality water (UHQ-water, produced on UHQ-PS,
Elga, UK). Poly(lactide-co-glycolide) (PLGA, 85:15,
Mn = 100 kDa, d = 1.9) was synthesized by a ring-
opening polymerization in bulk at 100 C using a bio-
compatible zirconium(IV) acetylacetonate initiator [17] in
the Centre of Polymer and Carbon Materials of the Polish
Academy of Sciences in Zabrze, Poland.
2.2 Vancomycin-loaded nanoparticles fabrication
PLGA nanoparticles with vancomycin (NPs) were fabri-
cated using a double emulsification/solvent evaporation
technique. 10 mg of antibiotic (solid—S) was ultrasoni-
cated (3 min, 40 % of the cycle, Sonics VibraCellTM,
USA) in a 3.34 % w/v solution of PLGA in dichlor-
omethane (3 ml, oil—O), producing the primary dispersion
(S/O) on ice. The primary dispersion was then added drop
by drop into 15 ml of 4 % w/v PVA solution on ice during
ultrasonication and formed a secondary phase (S/O/water).
Subsequently, the emulsion was stirred overnight
(500 rpm) to remove dichloromethane. The dispersion of
nanoparticles was centrifuged (14,000 rpm, 4 C, 20 min)
and flushed three times with UHQ-water. Obtained NPs
were freeze-dried for 48 h and stored at 4 C. Before fur-
ther analyses, the particles were redispersed in UHQ-water
using ultrasonication.
2.3 Size and zeta potential of nanoparticles
The size, the polydispersity and zeta potential of NPs were
determined by dynamic light scattering (DLS) and capil-
lary electrophoresis measurements using a Zetasizer Nano
ZS (Malvern Instruments) at 25 C.
2.4 Drug encapsulation and loading efficiencies
To determine the amount of encapsulated Vanc, the
supernatant obtained after NPs centrifugation was gathered
and examined fluorescently (kex.—340 nm, kem.—455 nm;
FLUOstar Omega, BMG Labtech) using the OPA assay
[18]. Encapsulation (%EE) and loading efficiency (%LE)
were determined according to the following equations:
%EE ¼ mass of Vanc in nanoparticles
=initial mass of Vanc in the system 100% ð1Þ
%LE ¼ mass of Vanc in nanoparticles
=mass of nanoparticles 100% ð2Þ
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2.5 Morphology of nanoparticles
Morphology of NPs was investigated using atomic force
microscopy (AFM). A microscopic glass slide (Thermo-
scientific, Menzel-Glaser, Germany) was hydrophilized by
10 min sonication in ethanol followed by 12 h drying at
room temperature and a drop of 0.1 % w/v suspension of
NPs in UHQ-water was placed on it. Topographic images
were recorded in contact mode on an Explorer AFM
(Thermomicroscopes, spring constant k = 0.02 N/m,
image size 3 lm 9 3 lm). All the images were processed
using SPMLab6.02 provided by the AFM manufacturer.
2.6 Preparation of hydrogel-based injectable system
A 1.4 % (w/v) solution of gellan gum was prepared in
UHQ-water at 90 C. After the temperature was decreased
to 50 C, a 1.0 % w/v suspension of NPs (encapsulated
antibiotic 0.09 % w/v) and dissolved antibiotic (free
antibiotic 0.1 % w/v) were added. Final antibiotic content
in the sample was 0.19 % w/v. To adjust the injectability,
the samples were cross-linked by 0.3 % (w/v) CaCl2 and
denoted as GG-Vanc-NPs. Reference samples were gellan
gum with 0.3 % (w/v) CaCl2 (denoted as GG) and gellan
gum with 0.3 % (w/v) CaCl2 and dissolved antibiotic
(denoted as GG-Vanc). In all the samples the mass per-
centage of gellan gum was 0.7 % (w/v).
2.7 Injectability
The injectability of GG and GG-Vanc-NPs samples was
studied by the method described by Ghadhri et al. [19].
Force curves and the maximal force (FMax) needed to expel
1 ml of the samples from the 3 ml syringe with a stan-
dardized needle (18G, 0.85 mm inner diameter and
1.45 mm outer diameter, Becton Dickinson) were mea-
sured in a compression test (Zwick 1435, Germany). The
crosshead speed of the testing machine was 50 mm/min.
2.8 Rheological characteristics
Rheological tests were performed for GG and GG-Vanc-
NPs (Physica MCR 501 Rheometer, Anton Paar, Graz,
Austria; Couette CC10/T200 coaxial geometry with a bob
diameter 10.002 mm, cup diameter 10.845 mm). To avoid
evaporation, a layer of paraffin oil was applied. Gelation
was analyzed by measuring storage and loss moduli (G’
and G’’) as a function of time during application of oscil-
latory sinusoidal deformation (0–30 min, frequency
f = 1 Hz, strain c = 0.01 %). Then (30–60 min) the gels
were broken by increasing strain (c = 0.01–100 %,
f = 1 Hz). In the last time interval (60–90 min) behavior
of gel after structures’ disruption was analyzed (f = 1 Hz,
c = 0.01 %). All measurements were performed at 37 C.
2.9 Drug release experiment
The release profiles of drug from NPs and GG-Vanc-NPs,
were analyzed. Dialysis bags (ZelluTransRoth, MWCO
12 kDa) were filled with 1 ml of NPs suspension (10 mg
NPs, containing in total 0.9 mg drug) or 1 ml of GG-Vanc-
NPs (containing in total 1.9 mg drug) and immediately
immersed in the vials with 20 ml of phosphate buffered
saline (PBS) at pH 7.2 and stirred (50 rpm) at 37 C. At
predetermined time intervals, 0.5 ml of PBS were collected
for up to 40 days of the experiment and the amount of drug
was measured with an OPA reagent [18].
2.10 Antimicrobial activity
In order to check antimicrobial activity of GG-Vanc-NPs,
agar diffusion tests were performed according to the Kirby-
Bauer method. Growth inhibition against Gram-positive
bacteria Staphylococcus aureus (SA1-KCR) and Staphy-
lococcus epidermidis (SE1-KCR) isolated from infected
joints (Krakow Centre of Rehabilitation and Orthopedics,
2012) was observed. Reference strains were S. aur-
eus DSM 24167 (Deutsche Sammlung von Mikroorganis-
men und Zellkulturen) and S. epidermidis ATCC 700296
(American Type Culture Collection). Tested strains were
incubated in 5 ml of BactoTM Tryptic Soy Broth (Bec-
ton Dickinson) for 16 h at 37 C and prepared at a con-
centration of 0.5 on the McFarland scale (1.5 9 108 CFU/
ml) in 0.7 % w/v NaCl solution. Then, the bacteria were
seeded on Mueller–Hinton agar plates (Difco). In the left
part of each plate a 3 mm well was made with a hole punch
into which a tube-shaped GG-Vanc-NPs (2 mm height,
3 mm diameter) was introduced. In the right part a similar
GG-Vanc-NPs sample was placed. As positive control
vancomycin discs (30 lg, Oxoid, UK) were applied, while
as negative control GG samples were tested. The plates
were then incubated at 37 C for 18 h and the zone of
microbes growth inhibition (mm) was measured using
Calibrating Viewer.
2.11 Biological tests with osteoblast-like MG-63
cells
Gellan gum solution was autoclaved, CaCl2 and Vanc
solutions were sterile-filtered and NPs were treated with
UV-light for 40 min. Cytocompatibility was analyzed by
the metabolic activity of MG-63 cells (European Collection
of Cell Cultures, Salisbury, UK) incubated in the extract
from samples done in Eagle’s minimal essential medium
(EMEM, PAN BIOTECH, Germany) supplemented with
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10 % fetal bovine serum, 1 % penicillin–streptomycin,
0.1 % sodium pyruvate (PAA, Austria). Cells cultured in
pure EMEM acted as a control. Extract was obtained by
incubation tube-shaped samples in EMEM for 24 h at
37 C (0.1 g of material per 1 ml of medium). The extract
was diluted in EMEM by factors of 1/1 (undiluted), 1/2 and
1/4. MG-63 cells (1.5 9 104 cells/cm2) were cultured in a
48-well plate (Nunclon) for 24 h. Afterwards the medium
was changed for extracts (1 ml) at the aforementioned
dilutions. After another 24 h and 6 days metabolic activity
was measured via reduction of resazurin in Alamar Blue
reagent (10 % (w/v) Resazurin solution in PBS, Sigma-
Aldrich). 0.05 ml of reagent was added, cells were incu-
bated for 4 h at 37 C and then the reduction was measured
via fluorescence (kex.—530 nm, kem.—590 nm; FLUOstar
Omega, BMG Labtech) and calculated as follows:
%Reduction of Alamar Blue ¼ Sx  Scontrol = S100%reduced

Scontrol 100% ð3Þ
where Sx is fluorescence of samples, Scontrol is fluorescence
of EMEM without cells, S100 %reduced is fluorescence of
reagent reduced in 100 % (reagent with EMEM was placed
in autoclave for 15 min at 121 C).
Cell attachment, distribution and viability were evalu-
ated on day 1 and 6 after live/dead staining (calcein AM/
propidium iodide, Sigma-Aldrich according to the manu-
facturer’s protocol) using a fluorescence microscope (Ax-
iovert 40, Carl Zeiss, Germany).
All results were expressed as a mean ± standard error
of the mean (S.E.M.) from 3 individual measurements
performed in triplicate (n = 9). Statistical analysis was
performed using the unpaired t-test. Significant differences
were assumed at *p\ 0.05; **p\ 0.01; ***p\ 0.001.
3 Results
3.1 Properties of vancomycin-loaded nanoparticles
NPs produced with a double emulsification (S/O/W) were
formed with average diameter 258 ± 11 nm and polydis-
persity index 0.240 ± 0.003. The diameter and polydis-
persity of empty nanoparticles were 234 ± 4 nm and
0.290 ± 0.029, respectively. A histogram presenting the
hydrodynamic diameter of NPs is shown in Fig. 1a. Elec-
trophoretic measurements showed that NPs had a negative
surface charge with a zeta potential of -25.9 ± 0.2 mV;
for comparison empty nanoparticles had zeta potential of
-30.5 ± 0.6 mV. AFM analysis confirmed that NPs were
smooth and spherical (Fig. 1b). The encapsulation and
loading efficiencies of Vanc in the NPs were 55.2 ± 0.5
and 8.8 ± 0.1 %, respectively.
3.2 Injectablity
To start extrusion of GG a force of at least 4.5 N was
needed and during expulsion the force changed from 4 to
11 N (Fig. 2a). Regarding extrusion of GG-Vanc-NPs, the
force needed to initiate the movement of the piston was ca.
5 N, whereas the force needed to continue the extrusion
was slightly higher and less variable (7–12 N), and no
blocking of the needle was observed (Fig. 2b). Maximal
extrusion force was 10.7 ± 1.3 and 11.3 ± 1.1 N for GG
and GG-Vanc-NPs, respectively.
3.3 Rheology assay
Gelation took 7 and 22 min for reference and loaded system,
respectively, and afterwards plateau phasewas reached.Data
regarding rheological properties in plateau (after leveling
off) for GG and GG-Vanc-NPs showed significantly higher
storage modulus (G’) than loss modulus (G’’) value during
and after gelation (Table 1, Assembling). The structure was
much more elastic than viscous and exhibited the ability to
self-organize after disruption by strain sweep deformation.
After breaking, the moduli returned to initial relation
(G’[G’’) and values were similar to those in the gelation
stage (Table 1, Reassembling).
3.4 Vancomycin release kinetics
For NPs (Fig. 3a) an initial burst release on day 1 amounting
to*260 lg was measured, which was*26 % of the total
encapsulated antibiotic. Thereafter, the delivery was more
sustained: 220–100 lg/10-day interval (in total *83 % of
the whole Vanc dose was liberated within 40 days). For GG-
Vanc (Fig. 3b), a burst release after day 1 was also observed,
which amounted to*340 lg (*34 % of total encapsulated
antibiotic). Thereafter, the release kinetics were less sus-
tained than for NPs: the delivered amount varied between
110 and 10 lg/10-day interval and the whole Vanc dose
almost exhausted up to day 20. ForGG-Vanc-NPs (Fig. 3c) a
burst release of *900 lg (*47 % of Vanc content) was
obtained that was followed by balanced delivery of
*120 lg/10-day interval. Up to day 40 a sustained delivery
phase was observed. In total, the system delivered*1.5 mg,
i.e.*80 % of Vanc.
3.5 Activity against Staphylococcus spp.
In Fig. 4 inhibition zones and microphotographs of agar
plates with Staphylococcus spp. cultured with GG-Vanc-
NPs are presented. The diameters obtained were in the
range 24.1–29 mm (depending on the way the samples
were placed and type of the strain). For the vancomycin
standards (30 lg) the zone diameter was 27–28 mm. For
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GG sample growth of Staphylococcus spp. was not inhib-
ited (data not shown).
3.6 Cytotoxicity with MG-63 cells
Metabolic activity studies performed on MG-63 osteoblast-
like cells on day 1 and 6 showed that cell function was not
significantly altered by incubation in GG-Vanc-NPs
extracts (Fig. 5a). Regarding more concentrated extracts, a
slight tendency to down regulate cells’ activity was seen,
but the differences were not significant. On day 6 the cells
increased their activity significantly as compared to day 1.
For all the samples at day 1 (Fig. 5b, upper row) the
cells showed spindle-shape or spread morphology resem-
bling that under pure cell culture media conditions (Con-
trol); most of the cells were green and viable and only some
dead cells were observed. At day 6 the cells were viable,
formed a monolayer and exhibited a high level of meta-
bolic activity.
4 Discussion
This study aimed to develop a new injectable system with
Vanc for osteomyelitis treatment. The hydrogel-based
structure of the injection contained a dissolved portion of
antibiotic, antibiotic-loaded nanoparticles and a cross-lin-
ker (Ca2?) that by ionotropic gelation ensured elasticity,
compactness and stability of the whole structure. The
system was characterized from the point of view of surgical
handling, precision of dosage, mechanical stability, rheol-
ogy and drug release kinetics. For in vitro evaluation, the
biological response of pathogens causing osteomyelitis
(Staphylococcus spp.) and osteoblast-like MG-63 cells
were investigated.
4.1 Vanc-loaded nanoparticles
Vancomicin is a model water-soluble antibiotic, widely
used in osteomyelitis treatment and prevention of osseous
staphylococci-derived infections [20]. However in order to
effectively encapsulate Vanc in a hydrophobic matrix (e.g.
PLGA) its hydrophilic character is an obstacle to achieve
high solubilization efficiencies. A rapid partitioning into
the external water phase occurred and finally 55.2 ± 0.5
and 8.4 ± 0.1 % of encapsulation and loading efficiencies,
respectively, were obtained. Our results are similar to those
obtained in other studies on vancomycin-loaded PLGA
particles of submicron size produced via double emulsifi-
cation [21]. The negative charge of PLGA nanoparticles
(-25.9 ± 0.2 mV) was due to ionization of carboxylic end
groups of the polymer and may be interpreted as an indi-
cator of suspension stability: the repulsion occurring pre-
vented phase separation due to aggregation [22]. The batch
of NPs also displayed low polydispersity (see Fig. 1a, b).
4.2 Handling of injectable system
Currently the low-traumatic therapies are strongly recom-
mended [23]. Here, great attention is paid to injections that
are site specific, easy to use and precisely fill the bony
defect [24]. In this study we showed that to sustain the GG
extrusion a variable pressure (reflected as force changes)
was needed (see Fig. 2a). This observation can be
Fig. 1 Histogram presenting
hydrodynamic diameter of NPs
obtained with Malvern Zetasizer
NanoZS (a), AFM
topographical image of NPs (b)
Table 1 Rheological characteristics of GG and GG-Vanc-NPs.
Storage modulus G’ and loss modulus G’’ values obtained during
gelation (assembling) of the matrix (f = 1 Hz, c = 0.01 %) and
reassembling of the matrix after breaking by strain deformation
(f = 1 Hz, c = 0.01 % – 100 %); n = 3
Sample Assembling Reassembling after
breaking
G’ (kPa) G’’ (kPa) G’ (kPa) G’’ (kPa)
GG 8.5 ± 0.9 0.5 ± 0.1 7.1 ± 0.7 0.5 ± 0.1
GG-Vanc-NPs 7.4 ± 1.5 0.4 ± 0.2 6.6 ± 0.9 0.4 ± 0.1
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connected with spatial inhomogeneities that result from
non-uniform distribution of cross-links arising during
ionotropic gelation (the higher the number of cross-links,
the more diversified the structure) [25]. Presumably, such
differences in forces applied on the piston resulted from
such structure disorders.
On the other hand, GG loaded with nanoparticles and
dissolved drug was more compact, bulky and exhibited a
paste-like character. The pressure necessary to initiate and
continue extrusion was slightly higher, but less variable,
enabling much more precise dosing.
According to recommendations themaximal extrusion force
(a measure of surgical handling) should be lower than 20 N
[26]. For GG-Vanc-NPs, an extrusion force of 11.3 ± 1.1 N
was measured which confirmed its easy handling during
application. The values were comparable to previously used
medical materials such as fillers for craniofacial surgery
(Restylene, Therafill, FMAX = 10–12 N) [27], tricalcium
phosphate pastes intended for bone filling (5.4 ± 1.1 to
18.5 ± 1.7 N) [28] or injectable hydrogel-based systems for
local delivery of bisphosphonates (9.5 ± 1.0 N) [29].
4.3 Rheological properties
Performing rheology studies enables understanding of the
development of structural alterations of parenteral formu-
lations during handling or administration, i.e. syringe filling
or injection [30]. Gellan gum natively follows cation-medi-
ated aggregation of the triplets of double helices into brittle
gel [12]. The character and mechanical properties of the
system were analyzed by a strain sweep deformation test. It
was observed that both samples were muchmore elastic than
viscous (more rubbery-like than fluid-like). NPs’ addition
neither significantly decreasedmechanical properties nor the
ability to self-assemble after disruption (transformation of
gel to sol was not obtained). The moduli values immediately
restored the initial state, i.e. significant domination of G’
over G’’. Such behavior, i.e. electrostatically-driven
Fig. 2 Force changes as a
function of piston distance
during injection of GG (a) and
GG-Vanc-NPs (b); the values of
maximal extrusion force (FMax,
mean ± SEM) are also shown
below the curves
Fig. 3 Vanc release profiles from a Vanc-loaded nanoparticles (1 ml
of 0.1 % w/v NPs suspension, antibiotic content 0.9 mg) b gellan
gum with antibiotic (1 ml of GG-Vanc, antibiotic content 1.0 mg) and
c injectable system (1 ml of GG-Vanc-NPs, antibiotic content
1.9 mg). Merged pictures presenting cumulative release (left axes,
squares) and 10-day doses (right axes, bars)
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immediate structure arrangement after destruction, was
previously described by Wang et al. for colloidal gels
obtained from gelatin nanospheres bearing opposite charges
[31].
4.4 Drug release profile
The antibiotic release kinetics from typical materials of
biomedical use (e.g. PMMA cements) are poorly charac-
terized. Cumulatively only 25 % of the drug is released,
whereas 60 % of the liberated dose is due to burst release.
As a result, very quickly (within 1–2 weeks) the drug
concentration falls well below therapeutic level [10, 32]. In
general there is a recommendation to deliver high doses
initially to clear tissue from bacterial biofilm, that should
be followed by sustained and prolonged delivery in order to
prevent microbial repopulation [32, 33].
For NPs (see Fig. 3a) we observed: (i) a burst phase,
(ii) a slowdown around day 10 and (iii) a fine, sustained
delivery of medium doses in the following 10-day inter-
vals. The first phase can be connected with diffusion of
the drug located in the subsurface region of NPs [34]. The
slowdown in drug release on day 10 possibly was related
to depletion of surface-associated drug [34]. In the last
phase the release dose was higher but constant. Possibly
along with degradation, porosities and channels accessible
for water were created (the morphology studies for NPs
showed an initially smooth surface without cavities) that
facilitated elution of the hydrophilic drug out of NPs,
indicating an erosion-diffusion drug release mechanism,
as shown in other studies [34]. Although the drug release
profile from NPs seems to comply with the demands of
the antimicrobial therapies, the use of unprocessed NPs is
rather questionable due to possible phagocytic uptake
[35].
For GG-Vanc the cumulative release curve (see Fig. 3b)
showed rapid release, slowing down with time, and soon
depletion of Vanc 10-day doses. Possibly it was caused by
fast leaching out of Vanc from GG structure, which shows
a mainly diffusion-controlled manner of release enhanced
by swelling [36]. Although the gel structure ensured
deformability and injectable properties, due to lack of a
sustained release phase its applicability in osteomyelitis
treatment is less advantageous.
The best results were observed for GG-Vanc-NPs (see
Fig. 3c)—the system exhibited both a very prominent burst
phase as well as a fine prolonged phase of sustain delivery.
Possibly, the mechanism of drug release in this case is a
combination of erosion-diffusion release enhanced by
hydrogel swelling, which are both of key importance from
the point of view of therapeutical success.
Fig. 4 Inhibition of Staphylococcus spp. (DSM 24167—reference
strain of S. aureus, SA1-KCR—isolate of S. aureus from infected
joint, ATCC 700296—reference strain of S. epidermidis, SE1-KCR—
isolate of S. epidermidis from infected joint) grown with GG-Vanc-
NPs. Microphotographs were taken on Petri dish (diameter 9 cm),
with a digital camera Olympus; the samples were introduced inside
the 3 mm agar well or placed directly on the agar, for the left and
right area of the Petri dish, respectively. Mean ± SEM
Fig. 5 Metabolic activity of MG-63 cells evaluated by reduction of
Alamar Blue (a) and live/dead staining (b) on 1 day or day 6 in
contact with GG-Vanc-NPs extracts diluted in EMEM by the factors
of 1/1, 1/2 or 1/4 and pure EMEM—Control; green are viable cells,
red are dead cells (Olympus Carl Zeiss Axiovert, Germany). Scale
bar 100 lm. Mean ± SEM; ***p\ 0.001 (Color figure online)
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4.5 Antimicrobial potential and cytocompatibility
To monitor antimicrobial activity both clinical isolates
taken from osteomyelitic joints and reference strains were
used. The latter are equally important to study selection
evasion of prophylaxis by tolerant strains or interspecies
transfer of antimicrobial resistance genes in the microen-
vironment of a biofilm [37]. Zones of inhibited growth
24–29 mm in diameter were obtained (see Fig. 4). Larger
zones occurred for GG-Vanc-NPs placed inside the agar
well than directly on the agar surface; after placement in
the well the higher contact area of the sample seemed to
facilitate drug transport. In other studies on polyurethane
scaffolds for bone wounds antimicrobial protection inhi-
bition zones of ca. 20 mm were obtained [10]. It can be
concluded that antibiotic released from GG-Vanc-NPs
preserved its antimicrobial activity, so processing did not
alter the pharmacological efficiency of Vanc. In vitro tests
performed in contact with MG-63 cells showed that the
system was cytocompatible with bone-forming cells
(see Fig. 5a, b).
5 Conclusion
The system based on vancomycin loaded nanoparticles and
vancomycin embedded in gellan gum matrix: (i) was easy
to apply (injectable), (ii) showed good mechanical prop-
erties (self-assembled after disruption by strain deforma-
tion), (iii) ensured local antibiotic delivery with an
advantageously high burst phase and a long sustained
phase, (iv) demonstrated antimicrobial activity against
Staphylococcus spp. and (v) was cytocompatible with
osteoblast-like cells. The system demonstrated potential for
the intrabone antibiotherapy of osteomyelitis.
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